Publications – KalVista Pharmaceuticals

Showing 7 out of 7

Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

Riedl MA, Farkas H, Aygören-Pürsün E, Psarros F, Soteres DF, M.D., Staevska M, Cancian M
New England Journal of Medicine

Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema

Feener EP, Davie RL, Murugesan N, Pethen SJ, Hampton SL, Smith MD, Audhya PK, Yea CM

Drugs and Drug Candidates

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

Cohn DM, Aygören-Pürsün E, Bernstein JA, Farkas H, Lumry WR, Maurer M, Zanichelli A, Iverson M, Hao J, Smith MD, Yea CM, Audhya PK, Riedl MA

Clinical Translation Allergy

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary Angiodema

Davie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S

Journal of Medicinal Chemistry

Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participants

Mutch P, Bashir M, Jung B, Yi P, Iverson M

Xenobiotica

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

Journal of Allergy and Clinical Immunology

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP

Clinical & Experimental Allergy

About

Science

Pipeline

Careers

Contact